Zymeworks (NASDAQ:ZYME) Insider Sells $1,036,047.87 in Stock

Key Points

  • Insider Paul Moore sold 39,741 Zymeworks shares for about $1.04 million at an average price of $26.07, reducing his stake by 54.07% to 33,756 shares.
  • Zymeworks’ board authorized a $200 million share repurchase plan, allowing the company to buy back up to 10.9% of its shares.
  • The company beat quarterly EPS estimates by $0.01 and reported revenue of $512.92 million, up 828.7% year over year. Analysts’ consensus rating was “Moderate Buy,” with a $43.25 average price target.

Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) insider Paul Moore sold 39,741 shares of Zymeworks stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $26.07, for a total transaction of $1,036,047.87. Following the completion of the sale, the insider owned 33,756 shares of the company's stock, valued at approximately $880,018.92. The trade was a 54.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Zymeworks Trading Up 0.8%

Shares of ZYME stock opened at $26.45 on Tuesday. The stock has a market cap of $1.83 billion, a P/E ratio of 50.87 and a beta of 1.32. The stock has a 50 day simple moving average of $27.26 and a 200 day simple moving average of $25.50. Zymeworks Inc. has a 1 year low of $21.52 and a 1 year high of $31.97.

Zymeworks (NASDAQ:ZYME - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.27 by $0.01. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The business had revenue of $512.92 million for the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the business posted ($0.26) earnings per share. The firm's quarterly revenue was up 828.7% compared to the same quarter last year. Analysts forecast that Zymeworks Inc. will post 1.31 EPS for the current year.




Zymeworks declared that its Board of Directors has authorized a stock buyback plan on Monday, November 16th that authorizes the company to repurchase $200 million in shares. This repurchase authorization authorizes the company to repurchase up to 10.9% of its stock through open market purchases. Share repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ZYME. Deutsche Bank set a $32.00 target price on Zymeworks in a research report on Wednesday, August 26th. HC Wainwright raised their price target on Zymeworks from $55.00 to $56.00 and gave the stock a "buy" rating in a research report on Tuesday, November 10th. JPMorgan Chase & Co. raised their price target on Zymeworks from $31.00 to $33.00 and gave the stock an "overweight" rating in a research report on Thursday, September 3rd. Citigroup boosted their price target on Zymeworks from $39.00 to $44.00 and gave the company a "buy" rating in a research note on Wednesday, November 11th. Finally, Citizens Jmp upped their price objective on shares of Zymeworks from $32.00 to $39.00 and gave the stock a "market outperform" rating in a research report on Friday. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zymeworks currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

Read Our Latest Analysis on ZYME

Institutional Trading of Zymeworks

Several large investors have recently made changes to their positions in the company. Nykredit A S bought a new position in Zymeworks in the second quarter valued at approximately $25,000. Sterling Capital Management LLC raised its position in Zymeworks by 813.3% during the third quarter. Sterling Capital Management LLC now owns 1,507 shares of the company's stock valued at $40,000 after purchasing an additional 1,342 shares in the last quarter. State of Wyoming bought a new stake in Zymeworks during the second quarter worth $73,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Zymeworks during the third quarter worth $96,000. Finally, State of Alaska Department of Revenue bought a new stake in Zymeworks during the third quarter worth $102,000. Institutional investors and hedge funds own 92.89% of the company's stock.

About Zymeworks

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company's lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

See Also

Insider Buying and Selling by Quarter for Zymeworks (NASDAQ:ZYME)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Zymeworks?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Zymeworks and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles